News Releases

 
News Releases
  Date Title and Summary View
Jun 6, 2017
-- Clinical Study Shows Drop in Proteinuria in Patients Treated with Avacopan for IgA Nephropathy (IgAN) -- -- Potential of CCR2 Inhibitor as a Therapeutic Treatment Option for FSGS Validated -- MOUNTAIN VIEW, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications ...
May 24, 2017
MOUNTAIN VIEW, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: ...
May 23, 2017
MOUNTAIN VIEW, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that the European Medicines Agency (EMA) has granted orphan medicinal product designation for avacopan (formerly CCX168) in t...
May 10, 2017
-- Phase III clinical trial of avacopan for the treatment of ANCA Vasculitis underway as Journal of American Society of Nephrology (JASN) publishes results of successful Phase II CLEAR clinical trial -- -- Received FDA Orphan Drug Designation for avacopan in the treatment of C3 Glomerulopathy (C3G) -- -- Conference call today at 5:00 p.m. Eas...
Apr 27, 2017
MOUNTAIN VIEW, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's first quarter 2017 financial results will be released after market close on Wednesday, May 10, 2017. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on Wednesday, May 10,...
Mar 22, 2017
MOUNTAIN VIEW, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for avacopan in the treatment of patie...
Mar 14, 2017
-- Expanded Vifor Pharma partnership now totals $155 million in upfront cash commitments, $1.2 billion in potential milestone payments, plus substantial royalties on potential net sales -- -- Initiated Phase III clinical trial of Avacopan for the treatment of ANCA Vasculitis -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN V...
Mar 1, 2017
MOUNTAIN VIEW, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's fourth quarter 2016 financial results will be released after market close on Tuesday, March 14, 2017. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on March 14, 2017 to...
Feb 28, 2017
MOUNTAIN VIEW, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 10:00 a.m. ET. The conference will be held at the Boston Marriott Cop...
Feb 14, 2017
-- ChemoCentryx retains all rights in the United States and China; Vifor Pharma gains additional marketing rights in Asia, including Japan and Middle Eastern markets -- ...
Page:
1
... NextLast
= add release to Briefcase